PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2098163
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2098163
Oncolytic Viral Therapy Market Insights, Competitive Landscape, and Market Forecast - 2033
The global Oncolytic Viral Therapy Market is projected to witness robust growth over the coming years as the healthcare industry increasingly adopts innovative cancer treatment approaches. Oncolytic viral therapy has emerged as a promising immunotherapy strategy that selectively targets and destroys cancer cells while stimulating the body's immune response against tumors. Growing investments in oncology research, continuous advancements in biotechnology, and increasing demand for targeted cancer therapies are creating favorable conditions for market expansion. The global market is expected to be valued at US$ 297.8 Mn in 2026 and is forecast to reach US$ 1,157.3 Mn by 2033, expanding at a CAGR of 21% during the forecast period.
Introduction
Cancer remains one of the leading causes of mortality worldwide, creating a strong need for advanced therapeutic solutions that offer improved treatment outcomes with fewer adverse effects. Oncolytic viral therapy has gained considerable attention because of its ability to selectively infect malignant cells while preserving healthy tissues. These viruses not only destroy tumors directly but also activate the immune system to recognize and eliminate cancer cells throughout the body.
Continuous scientific discoveries, expanding clinical studies, and rising acceptance of immunotherapy are strengthening the commercial potential of oncolytic viral therapies. Pharmaceutical companies and biotechnology organizations are actively developing new viral platforms designed to improve treatment effectiveness across multiple cancer indications.
Market Insights
The Oncolytic Viral Therapy Market is entering a new phase of development as research activities continue to generate encouraging clinical results. Improvements in genetic engineering have enabled researchers to enhance viral selectivity, increase therapeutic efficacy, and reduce treatment related risks.
The market is anticipated to increase from US$ 297.8 Mn in 2026 to US$ 1,157.3 Mn by 2033, registering a healthy 21% CAGR during the forecast period. Rising investment in oncology innovation, expanding partnerships between biotechnology firms and research institutions, and the growing number of clinical trials are expected to support sustained market growth.
Increasing awareness regarding personalized medicine and precision oncology is also encouraging healthcare providers to explore viral therapies as part of comprehensive cancer treatment strategies.
Market Drivers
The rising incidence of cancer worldwide continues to generate demand for innovative treatment solutions capable of improving patient survival and quality of life.
Growing adoption of immunotherapy has created significant opportunities for oncolytic viral therapies, which complement existing treatment approaches by enhancing immune system activity against tumors.
Rapid progress in viral engineering technologies has enabled the development of safer and more effective therapeutic viruses with improved tumor targeting capabilities.
Increasing research funding from public and private organizations is accelerating product development while supporting the expansion of clinical pipelines.
The growing number of collaborations between biotechnology companies, pharmaceutical manufacturers, and academic institutions is further contributing to innovation across the market.
Business Opportunities
The Oncolytic Viral Therapy Market presents considerable opportunities for biotechnology companies, pharmaceutical manufacturers, research organizations, and healthcare providers.
Combination therapies are expected to become a major area of commercial development. Integrating oncolytic viruses with chemotherapy, radiotherapy, immune checkpoint inhibitors, and targeted therapies may improve clinical outcomes while expanding the range of treatable cancers.
Emerging healthcare markets also represent attractive growth opportunities as governments increase healthcare investments and strengthen oncology treatment infrastructure.
Companies investing in advanced manufacturing technologies, viral engineering capabilities, and strategic research collaborations are expected to gain a competitive advantage as demand for innovative cancer therapies continues to increase.
Regional Analysis
North America is expected to remain the leading regional market due to its well established biotechnology industry, advanced healthcare infrastructure, and significant investments in cancer research. The region also benefits from strong clinical development activities and early adoption of innovative treatment technologies.
Europe continues to strengthen its position through expanding research programs, increasing biotechnology investments, and supportive regulatory initiatives that encourage innovation in cancer therapeutics.
Asia Pacific is expected to experience substantial growth owing to rising healthcare expenditure, improving research capabilities, expanding pharmaceutical manufacturing, and increasing cancer awareness across the region.
Latin America is witnessing gradual improvements in healthcare infrastructure, creating opportunities for advanced oncology treatments.
The Middle East and Africa are also expected to record steady market development as governments continue investing in healthcare modernization and cancer care services.
Competitive Landscape
Competition within the global Oncolytic Viral Therapy Market is intensifying as companies focus on expanding their product pipelines and strengthening research capabilities.
Leading market participants are investing heavily in clinical trials, next generation viral technologies, and strategic collaborations aimed at accelerating product development. Many organizations are also exploring personalized treatment approaches and combination therapies to enhance therapeutic outcomes and expand commercial opportunities.
Continuous innovation, regulatory progress, and increasing investment in oncology research are expected to shape the competitive landscape throughout the forecast period.
Future Outlook
The future of the Oncolytic Viral Therapy Market appears highly promising as advances in cancer immunotherapy continue to transform global oncology treatment practices.
Increasing clinical success, expanding research activities, and ongoing improvements in viral engineering technologies are expected to support long term market growth. The growing preference for targeted therapies with improved safety profiles will further strengthen market demand.
As pharmaceutical companies, biotechnology firms, and research institutions continue to invest in innovative treatment platforms, the market is expected to witness sustained expansion through 2033.
Key Players
- Amgen Inc.
- Oncolytics Biotech Inc.
- Replimune Group Inc.
- Sorrento Therapeutics Inc.
- Transgene SA
- PsiOxus Therapeutics Ltd.
- SillaJen Inc.
- Targovax ASA
- Genelux Corporation
- Vyriad Inc.
- TILT Biotherapeutics
- Cold Genesys Inc.
- Oncolys BioPharma
- Viralytics Ltd.
- Lokon Pharma AB
Market Segmentation
By Product Type
- Herpes simplex virus
- Adenovirus
- Vaccinia virus
- Reovirus
- Measles virus
- Others
By Application
- Melanoma
- Breast cancer
- Head and neck cancer
- Bladder Cancer
- Prostate Cancer
- Lung Cancer
- Others
By Development Stage
- Commercial
- Pipeline Phase
- Pre clinical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Table of Contents
1. Executive Summary
- 1.1. Global Oncolytic Viral Therapy Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2026
- 1.5. Analyst Recommendations
2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. COVID-19 Impact Analysis
- 2.5. Porter's Fiver Forces Analysis
- 2.6. Impact of Russia-Ukraine Conflict
- 2.7. PESTLE Analysis
- 2.8. Regulatory Analysis
- 2.9. Price Trend Analysis
- 2.9.1. Current Prices and Future Projections, 2025-2033
- 2.9.2. Price Impact Factors
3. Global Oncolytic Viral Therapy Market Outlook, 2020-2033
- 3.1. Global Oncolytic Viral Therapy Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
- 3.1.1. Herpes simplex virus
- 3.1.2. Adenovirus
- 3.1.3. Vaccinia virus
- 3.1.4. Reovirus
- 3.1.5. Measles virus
- 3.1.6. Others
- 3.2. Global Oncolytic Viral Therapy Market Outlook, by Application, Value (US$ Mn), 2020-2033
- 3.2.1. Melanoma
- 3.2.2. Breast cancer
- 3.2.3. Head and neck cancer
- 3.2.4. Bladder Cancer
- 3.2.5. Prostate Cancer
- 3.2.6. Lung Cancer
- 3.2.7. Others
- 3.3. Global Oncolytic Viral Therapy Market Outlook, by Development Stage, Value (US$ Mn), 2020-2033
- 3.3.1. Commercial
- 3.3.2. Pipeline Phase
- 3.3.3. Pre-clinical
- 3.4. Global Oncolytic Viral Therapy Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
- 3.4.1. Hospital Pharmacies
- 3.4.2. Retail Pharmacies
- 3.4.3. Online Pharmacies
- 3.5. Global Oncolytic Viral Therapy Market Outlook, by Region, Value (US$ Mn), 2020-2033
- 3.5.1. North America
- 3.5.2. Europe
- 3.5.3. Asia Pacific
- 3.5.4. Latin America
- 3.5.5. Middle East & Africa
4. North America Oncolytic Viral Therapy Market Outlook, 2020-2033
- 4.1. North America Oncolytic Viral Therapy Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
- 4.1.1. Herpes simplex virus
- 4.1.2. Adenovirus
- 4.1.3. Vaccinia virus
- 4.1.4. Reovirus
- 4.1.5. Measles virus
- 4.1.6. Others
- 4.2. North America Oncolytic Viral Therapy Market Outlook, by Application, Value (US$ Mn), 2020-2033
- 4.2.1. Melanoma
- 4.2.2. Breast cancer
- 4.2.3. Head and neck cancer
- 4.2.4. Bladder Cancer
- 4.2.5. Prostate Cancer
- 4.2.6. Lung Cancer
- 4.2.7. Others
- 4.3. North America Oncolytic Viral Therapy Market Outlook, by Development Stage, Value (US$ Mn), 2020-2033
- 4.3.1. Commercial
- 4.3.2. Pipeline Phase
- 4.3.3. Pre-clinical
- 4.4. North America Oncolytic Viral Therapy Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
- 4.4.1. Hospital Pharmacies
- 4.4.2. Retail Pharmacies
- 4.4.3. Online Pharmacies
- 4.5. North America Oncolytic Viral Therapy Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 4.5.1. U.S. Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 4.5.2. U.S. Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 4.5.3. U.S. Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 4.5.4. U.S. Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 4.5.5. Canada Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 4.5.6. Canada Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 4.5.7. Canada Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 4.5.8. Canada Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Oncolytic Viral Therapy Market Outlook, 2020-2033
- 5.1. Europe Oncolytic Viral Therapy Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
- 5.1.1. Herpes simplex virus
- 5.1.2. Adenovirus
- 5.1.3. Vaccinia virus
- 5.1.4. Reovirus
- 5.1.5. Measles virus
- 5.1.6. Others
- 5.2. Europe Oncolytic Viral Therapy Market Outlook, by Application, Value (US$ Mn), 2020-2033
- 5.2.1. Melanoma
- 5.2.2. Breast cancer
- 5.2.3. Head and neck cancer
- 5.2.4. Bladder Cancer
- 5.2.5. Prostate Cancer
- 5.2.6. Lung Cancer
- 5.2.7. Others
- 5.3. Europe Oncolytic Viral Therapy Market Outlook, by Development Stage, Value (US$ Mn), 2020-2033
- 5.3.1. Commercial
- 5.3.2. Pipeline Phase
- 5.3.3. Pre-clinical
- 5.4. Europe Oncolytic Viral Therapy Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
- 5.4.1. Hospital Pharmacies
- 5.4.2. Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.5. Europe Oncolytic Viral Therapy Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 5.5.1. Germany Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 5.5.2. Germany Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 5.5.3. Germany Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 5.5.4. Germany Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 5.5.5. Italy Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 5.5.6. Italy Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 5.5.7. Italy Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 5.5.8. Italy Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 5.5.9. France Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 5.5.10. France Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 5.5.11. France Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 5.5.12. France Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 5.5.13. U.K. Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 5.5.14. U.K. Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 5.5.15. U.K. Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 5.5.16. U.K. Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 5.5.17. Spain Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 5.5.18. Spain Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 5.5.19. Spain Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 5.5.20. Spain Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 5.5.21. Russia Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 5.5.22. Russia Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 5.5.23. Russia Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 5.5.24. Russia Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 5.5.25. Rest of Europe Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 5.5.26. Rest of Europe Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 5.5.27. Rest of Europe Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 5.5.28. Rest of Europe Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Oncolytic Viral Therapy Market Outlook, 2020-2033
- 6.1. Asia Pacific Oncolytic Viral Therapy Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
- 6.1.1. Herpes simplex virus
- 6.1.2. Adenovirus
- 6.1.3. Vaccinia virus
- 6.1.4. Reovirus
- 6.1.5. Measles virus
- 6.1.6. Others
- 6.2. Asia Pacific Oncolytic Viral Therapy Market Outlook, by Application, Value (US$ Mn), 2020-2033
- 6.2.1. Melanoma
- 6.2.2. Breast cancer
- 6.2.3. Head and neck cancer
- 6.2.4. Bladder Cancer
- 6.2.5. Prostate Cancer
- 6.2.6. Lung Cancer
- 6.2.7. Others
- 6.3. Asia Pacific Oncolytic Viral Therapy Market Outlook, by Development Stage, Value (US$ Mn), 2020-2033
- 6.3.1. Commercial
- 6.3.2. Pipeline Phase
- 6.3.3. Pre-clinical
- 6.4. Asia Pacific Oncolytic Viral Therapy Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
- 6.4.1. Hospital Pharmacies
- 6.4.2. Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.5. Asia Pacific Oncolytic Viral Therapy Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 6.5.1. China Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 6.5.2. China Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 6.5.3. China Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 6.5.4. China Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 6.5.5. Japan Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 6.5.6. Japan Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 6.5.7. Japan Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 6.5.8. Japan Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 6.5.9. South Korea Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 6.5.10. South Korea Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 6.5.11. South Korea Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 6.5.12. South Korea Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 6.5.13. India Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 6.5.14. India Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 6.5.15. India Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 6.5.16. India Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 6.5.17. Southeast Asia Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 6.5.18. Southeast Asia Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 6.5.19. Southeast Asia Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 6.5.20. Southeast Asia Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 6.5.21. Rest of SAO Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 6.5.22. Rest of SAO Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 6.5.23. Rest of SAO Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 6.5.24. Rest of SAO Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Oncolytic Viral Therapy Market Outlook, 2020-2033
- 7.1. Latin America Oncolytic Viral Therapy Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
- 7.1.1. Herpes simplex virus
- 7.1.2. Adenovirus
- 7.1.3. Vaccinia virus
- 7.1.4. Reovirus
- 7.1.5. Measles virus
- 7.1.6. Others
- 7.2. Latin America Oncolytic Viral Therapy Market Outlook, by Application, Value (US$ Mn), 2020-2033
- 7.2.1. Melanoma
- 7.2.2. Breast cancer
- 7.2.3. Head and neck cancer
- 7.2.4. Bladder Cancer
- 7.2.5. Prostate Cancer
- 7.2.6. Lung Cancer
- 7.2.7. Others
- 7.3. Latin America Oncolytic Viral Therapy Market Outlook, by Development Stage, Value (US$ Mn), 2020-2033
- 7.3.1. Commercial
- 7.3.2. Pipeline Phase
- 7.3.3. Pre-clinical
- 7.4. Latin America Oncolytic Viral Therapy Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.5. Latin America Oncolytic Viral Therapy Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 7.5.1. Brazil Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 7.5.2. Brazil Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 7.5.3. Brazil Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 7.5.4. Brazil Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 7.5.5. Mexico Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 7.5.6. Mexico Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 7.5.7. Mexico Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 7.5.8. Mexico Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 7.5.9. Argentina Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 7.5.10. Argentina Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 7.5.11. Argentina Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 7.5.12. Argentina Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 7.5.13. Rest of LATAM Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 7.5.14. Rest of LATAM Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 7.5.15. Rest of LATAM Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 7.5.16. Rest of LATAM Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Oncolytic Viral Therapy Market Outlook, 2020-2033
- 8.1. Middle East & Africa Oncolytic Viral Therapy Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
- 8.1.1. Herpes simplex virus
- 8.1.2. Adenovirus
- 8.1.3. Vaccinia virus
- 8.1.4. Reovirus
- 8.1.5. Measles virus
- 8.1.6. Others
- 8.2. Middle East & Africa Oncolytic Viral Therapy Market Outlook, by Application, Value (US$ Mn), 2020-2033
- 8.2.1. Melanoma
- 8.2.2. Breast cancer
- 8.2.3. Head and neck cancer
- 8.2.4. Bladder Cancer
- 8.2.5. Prostate Cancer
- 8.2.6. Lung Cancer
- 8.2.7. Others
- 8.3. Middle East & Africa Oncolytic Viral Therapy Market Outlook, by Development Stage, Value (US$ Mn), 2020-2033
- 8.3.1. Commercial
- 8.3.2. Pipeline Phase
- 8.3.3. Pre-clinical
- 8.4. Middle East & Africa Oncolytic Viral Therapy Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
- 8.4.1. Hospital Pharmacies
- 8.4.2. Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.5. Middle East & Africa Oncolytic Viral Therapy Market Outlook, by Country, Value (US$ Mn), 2020-2033
- 8.5.1. GCC Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 8.5.2. GCC Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 8.5.3. GCC Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 8.5.4. GCC Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 8.5.5. South Africa Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 8.5.6. South Africa Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 8.5.7. South Africa Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 8.5.8. South Africa Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 8.5.9. Egypt Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 8.5.10. Egypt Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 8.5.11. Egypt Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 8.5.12. Egypt Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 8.5.13. Nigeria Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 8.5.14. Nigeria Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 8.5.15. Nigeria Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 8.5.16. Nigeria Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 8.5.17. Rest of Middle East Oncolytic Viral Therapy Market Outlook, by Product Type, 2020-2033
- 8.5.18. Rest of Middle East Oncolytic Viral Therapy Market Outlook, by Application, 2020-2033
- 8.5.19. Rest of Middle East Oncolytic Viral Therapy Market Outlook, by Development Stage, 2020-2033
- 8.5.20. Rest of Middle East Oncolytic Viral Therapy Market Outlook, by Distribution Channel, 2020-2033
- 8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
- 9.1. Company Vs Segment Heatmap
- 9.2. Company Market Share Analysis, 2025
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Amgen Inc.
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Developments
- 9.4.2. Oncolytics Biotech Inc.
- 9.4.3. Replimune Group Inc.
- 9.4.4. Sorrento Therapeutics Inc.
- 9.4.5. Transgene SA
- 9.4.6. PsiOxus Therapeutics Ltd.
- 9.4.7. SillaJen Inc.
- 9.4.8. Targovax ASA
- 9.4.9. Genelux Corporation
- 9.4.10. Vyriad Inc.
- 9.4.1. Amgen Inc.
10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
